focus -WSS

focus

author：comprehensive 2025-08-12 06:43:19 - browse：27793

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What the cancer research community can learn from the Covid response

WSS

How climate

Hospital price transparency does save money, advocate argues

Dramatically reducing cancer deaths requires the PASTEUR Act

Humana, CVS hope to turn members into patients at clinics

For BCIs, commercial hurdles may be bigger than scientific ones

STAT Summit: Biotech founders on deal

leisure time

focus

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

My superpower is killing ticks

State Dept. review finds Biden bears some blame for Afghanistan failures

The explosion of genetic testing requires a new approach

Walensky prepares to leave CDC — and Congress — behind

White House drug shortage group privately met with industry

Novavax promises a turnaround & Lilly roils the obesity market

Humana, CVS hope to turn members into patients at clinics

Virginia high school admissions case could be legal follow

A cyberattack has disrupted hospitals and health care in several states

knowledge

ProMED, early warning system on disease outbreaks, in peril

Dramatically reducing cancer deaths requires the PASTEUR Act

What Mike Pence has said that could be used in a Donald Trump trial

Microsoft strikes partnership with Duke Health to advance health AI

Humana, CVS hope to turn members into patients at clinics

Lawmakers consider Medicare pay reforms for doctors

leisure time

entertainment

entertainment

focus